Nuvalent's $124 Share Sale to GSK Under Fiduciary Duty Probe
NUVL•Nuvalent agreed to be acquired by GSK plc for $124.00 per share in cash under terms that may limit superior competing bids. Halper Sadeh LLC is investigating this transaction for potential breaches of fiduciary duty and may seek increased consideration for shareholders.
1. Transaction Details
Nuvalent has entered into a definitive agreement to be acquired by GSK plc for $124.00 per share in cash. The deal includes provisions that may restrict rival bids and limit competing offers, potentially locking in the current price.
2. Legal Investigation
Halper Sadeh LLC has launched an inquiry into potential breaches of fiduciary duty by Nuvalent’s board and advisors. The firm is assessing whether insiders receive disproportionate benefits and may pursue enhanced shareholder compensation on a contingent fee basis.
